Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
News Aug 20, 2008
MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection and cardiovascular and renal ischemia-reperfusion injury.
“This agreement marks an important milestone in our MASP-2 program, and ensures that Omeros can access high-affinity, fully human antibodies against MASP-2,” stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. “We are impressed by Afftech’s technology, track record and personnel, and look forward to our collaboration.”
Under this collaboration, Omeros, based on its exclusive intellectual property position, will continue to advance the development of its MASP-2 program.
Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen™ platform and engineering methods, to generate fully human MASP-2 antibodies for Omeros.
Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros. No further terms of the agreement were disclosed.
“We are excited about this collaboration with Omeros,” said Martin Welschof, Ph.D., CEO of Affitech. “Omeros’ proprietary MASP-2 program is focused on a target with broad commercial applications, and provides Affitech the opportunity to apply our expertise, human antibody library and screening platform to a non-cancer disease field. We believe that our proven technology, together with Omeros’ intellectual property position and development capabilities, can yield a new and clinically important class of anti-inflammatory therapeutics.”